Feb 19,2025
Clinical recruitment (Research Unit: Sun Yat-sen University Cancer Center)
Subjects who are fully informed of the purpose, benefits, and risks of this study, voluntarily participate in the study. Histologically or cytologically confirmed unresectable locally advanced or metastatic solid tumors that have failed systemic standard treatment or for which there is currently no effective standard treatment, such as hepatocellular carcinoma, cervical cancer, prostate cancer, and melanoma, etc. At least one lesion that cannot be surgically resected and is suitable for direct intratumoral injection or image-guided intratumoral injection (lesion longest diameter (LD) 1-5cm, including boundary values). Age 18-75 years old (including boundary values).
View Details19
2025/02
Clinical recruitment (Research Unit: Xiangya Hospital Central South University)
1. Age 18-75 years old (inclusive); Gender unrestricted; 2. Clinically diagnosed with pancreatic cancer; 3. Resectable pancreatic cancer based on surgical assessment, clinical stage based on imaging assessment: T1-3, N any, M0; 4. Able to start adjuvant therapy no later than 12 weeks post-surgery. Adjuvant chemotherapy options include gemcitabine and capecitabine. 5. No serious hematological, hepatic, renal, coagulation or cardiac dysfunction;
03
2024/09
51% of clinical ADC drugs in China enter phase II and beyond trials
03
2024/09
Adult transplant recipients with CMV infection or disease bring new treatment options
03
2024/09
Global research and development of cancer vaccines to prevent and treat cancer
03
2024/09
Pien Tze Huang Pharmaceutical Another Innovative Tumor Drug Approved for Clinical
DLBCL is the most common non-Hodgkin lymphoma
03
2024/09
The enhanced version of oncolytic virus is launched to "dissolve" cancer cells is its unique trick.
Oncolytic viruses can "lyse" tumor cells"
03
2024/09
Legendary Bio announced that the company's self-developed cell therapy product, Kawei Di.®
03
2024/09
Medical and health industry innovation continues to emerge
03
2024/09
03
2024/09
2024 Antineoplastic Drug Innovation R & D Conference
03
2024/09
Study on Innovative Drug of Oncolytic Virus
Focus on us
Contact Information
Monday to Friday 9:00~17:00
Rooms 801-808 and 901-908, Building H, No. 3 Jiu Quan Road, Huangpu District, Guangzhou City
Copyright©2024 Virotech Pharmaceutical Technology Co., Ltd.
